A study published to evaluate the efficacy and safety of favipiravir has concluded that the drug has shown positive results in the treatment of mild to moderate cases of Covid-19 disease.
In the International Journal of Infectious Diseases.
The significant improvement in the time required for clinical cure suggests that favipiravir may be beneficial in mild to moderate Covid-19, the study states. Taking favipiravir has improved clinical healing in about three days and has cleared the infection two days faster than with standard treatment.
Considering that favipiravir, a drug that is being investigated in many countries for the treatment of Covid-19, the treatment produced a significant improvement in the time to clinical cure and may be a safe and effective treatment in mild to moderate infection. moderate by coronavirus.
In stating the method, the study mentions that it was carried out in adults in the age group of 18 to 75 years who had tested positive for Covid-19 with the RT-PCR test mechanism and showed mild to moderate symptoms. The study also included asymptomatic people during the course of infection. He concludes that the 1800 mg dose on day one and 800 mg of the drug over a 14 day period can ideally be effective.
The study also measured the time it takes for a patient to heal.
“While no statistically significant difference was achieved on the primary endpoint, statistically significant results were seen on the clinically significant secondary endpoint of time to clinical cure,” the study highlights.
He adds: “There was also a statistically significant difference in the time to first use of oxygen, although this observation should be interpreted with the greatest caution due to the small number of patients (7 in each treatment group) who required supplemental oxygen supply in this population. . Additionally, when assessing the severity of Covid-19, patients with moderate Covid-19 showed a statistically significant benefit with respect to clinical cure time. “
Favipiravir, according to the study, was found to be safe and well-tolerated in this study, despite possible over-reporting bias of TEAE in open-label trials.
“There were no new safety signs or adverse events that led to drug discontinuation or dosage regimen change; a single patient in the control group experienced an SAE, acute respiratory distress syndrome, which caused death, ”he says.
.
